Ruben P A van Eijk
Overview
Explore the profile of Ruben P A van Eijk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ros L, Sleutjes B, Goedee H, Asselman F, Cuppen I, van Eijk R, et al.
Muscle Nerve
. 2025 Mar;
PMID: 40028690
Introduction/aims: Survival Motor Neuron 1 (SMN1)-related spinal muscular atrophy (SMA) is characterized by α-motor neuron degeneration, with sensory function assumed to be clinically preserved. However, recent studies in severely affected...
2.
van Eijk R, Steyn F, Janse van Mantgem M, Schmidt A, Meyjes M, Allen S, et al.
Brain Commun
. 2025 Feb;
7(1):fcaf063.
PMID: 40008327
Metabolic imbalance is associated with amyotrophic lateral sclerosis progression. Impaired glucose oxidation and increased reliance on fatty acid oxidation contribute to reduced metabolic flexibility and faster disease progression in amyotrophic...
3.
Kopsky D, Vrancken A, van Eijk R, Alvarez-Jimenez R, Szadek K, Liebregts R, et al.
Pharmaceuticals (Basel)
. 2025 Feb;
18(2).
PMID: 40006041
: Treatment of painful diabetic neuropathy (PDN) poses several challenges due to the limited effectiveness, high incidence of side effects, and potential drug interactions of oral neuropathic pain medication. Lacking...
4.
Benatar M, Mcdermott C, Turner M, van Eijk R
Brain
. 2025 Feb;
PMID: 39908190
No abstract available.
5.
6.
7.
van Eijk R, van Loon F, van Unnik J, Weemering D, Seitidis G, Mavridis D, et al.
J Neurol
. 2024 Dec;
272(1):40.
PMID: 39666202
Objectives: Attrition due to adverse events and disease progression impacts the integrity and generalizability of clinical trials. The aim of this study is to provide evidence-based estimates of attrition for...
8.
Benatar M, Mcdermott C, Turner M, van Eijk R
Brain
. 2024 Dec;
PMID: 39657109
There is a long history in amyotrophic lateral sclerosis (ALS) of promoting therapies based on Phase 2 data, which then fail in Phase 3 trials. Experience suggests that studies of...
9.
van Loon F, Seitidis G, Mavridis D, van Unnik J, Weemering D, van den Berg L, et al.
BMJ Open
. 2024 Nov;
14(10):e087970.
PMID: 39486809
Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal neurogenerative disease with no effective treatment to date. Despite numerous clinical trials, the majority of studies have been futile in their effort...
10.
Ziser L, van Eijk R, Kiernan M, McRae A, Henderson R, Schultz D, et al.
Eur J Neurol
. 2024 Oct;
32(1):e16532.
PMID: 39475283
Background And Purpose: Given the accepted multistep process of disease causation in amyotrophic lateral sclerosis (ALS), the present study was undertaken to determine the number of steps required for disease...